



Estrogen for the Treatment and Prevention of Breast Cancer

Guest Editor:

Prof. Dr. Virgil Craig Jordan

Department of Breast Medical
Oncology, MD Anderson Cancer
Center, University of Texas, 1515
Holcombe Blvd., Unit 1354,
Houston, TX 77030, USA

Deadline for manuscript
submissions:

closed (30 April 2024)

Message from the Guest Editor

Estrogen exerts a significant influence on the development of breast cancer, primarily by binding to cellular estrogen receptors (ERs). Breast cancer can be categorized into two subtypes on the basis of the presence of ERs: ER-positive and ER-negative. In hormone receptor-positive (HR+) breast cancer, ERs serve as the principal transcription factors driving oncogenesis and play dual roles as both predictor and target of antiestrogen therapy response. In the case of ER α -negative breast cancer, a combination of chemotherapy and molecular-targeted drugs is commonly employed, with potential effectiveness anticipated through immune checkpoint inhibitors. Additionally, hormone therapies may prove efficacious in instances where other hormone receptors such as androgen and glucocorticoid receptors are expressed in ER α -negative breast cancer. The involvement of germline BRCA1/2 mutations in both ER-negative and ER-positive breast cancer pathogenesis is well established; however, numerous unknown factors persist regarding the pathological characteristics, genetic background, and immunological features associated with ER α -negative breast cancer.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)